PSA screening: What do you tell primary care docs?

"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

The WATER IV PCa will assess Aquablation vs radical prostatectomy in patients with grade group 1 to 3 localized prostate cancer.

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer.

Findings from GETUG 14 show short-term ADT with high-dose radiotherapy provided 5-year improved efficacy without increased risk of toxicity.